Skip to main content

Clinical Trials Using Carfilzomib

Review the clinical trials studying carfilzomib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Status: Active
Location: 16 locations
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 14 locations
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Status: Active
Location: 14 locations
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 12 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Status: Active
Location: 7 locations
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Status: Active
Location: 6 locations
Iberdomide-Combinations for the Treatment of Positive Minimal Residual Disease (>10-5) after Autologous Hematopoietic Cell Transplantation as Upfront Therapy in Patients with Multiple Myeloma, The COMMANDER Trial
Status: Active
Location: 5 locations
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 4 locations
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 4 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
A Study of Daratumumab
Status: Active
Location: 3 locations
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Status: Active
Location: 5 locations
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Status: Active
Location: 3 locations
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Status: Active
Location: 3 locations
Iberdomide, Carfilzomib, and Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Location: 2 locations
Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin With or Without Autologous Stem Cell Transplantation for the Treatment Relapsed or Refractory Multiple Myeloma or Newly Diagnosed, High Risk Multiple Myeloma
Status: Active
Location: 2 locations
Carfilzomib in Combination with Sotorasib for the Treatment of Patients with KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients with Extramedullary Disease
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone for Treatment of Relapsed or Recurrent Multiple Myeloma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Carfilzomib-Based Chemotherapy before Autologous Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
SX-682 in Combination with Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Status: Active
Location: 2 locations
Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy
Status: Temporarily Closed to Accrual
Location: 2 locations